Syntara (ASX: SNT) has expanded a Phase 1b study of its next-generation topical anti-fibrotic drug candidate SNT-9465 developed to improve the structure and app...
Market Samachar is a news aggregator. This article was originally published by smallcaps.com.au. Tap the button above to read the full story on their site.